The diabetic market is becoming one of the most important market for the large pharma. The drug delivery developed by spph has good chance if it was licensed to a large pharma who can spend the money for the clinical phases. They could get a fast track but considering it's not a big pharma requesting, it is unlikely it be granted without at least a 200 patient clinical trial. This would cost a minimum of $500,000 but the company does not have funds to pay anyone or anything. Dr arella has gone back to teaching to pay his mortgage and therefore not much is being done to get the financing
Dr arella has great contacts in the middle east and it still remains the best option for the company. I'm not suggesting a deal with hail first pharma since that ship has sailed but other contacts of dr arella.
Market Data 
Markets 
AI
